Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Non Operating Income (2016 - 2025)

Fennec Pharmaceuticals' Non Operating Income history spans 15 years, with the latest figure at -$2.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 208.91% year-over-year to -$2.1 million, compared with a TTM value of -$3.4 million through Dec 2025, changed N/A, and an annual FY2025 reading of -$3.4 million, changed N/A over the prior year.
  • Non Operating Income for Q4 2025 was -$2.1 million at Fennec Pharmaceuticals, down from -$449000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $2.0 million in Q4 2024, with the low at -$2.1 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$402894.7, with a median of -$449000.0 recorded in 2025.
  • Year-over-year, Non Operating Income soared 2211.11% in 2021 and then plummeted 1483.33% in 2022.
  • Tracing FENC's Non Operating Income over 5 years: stood at -$12000.0 in 2021, then tumbled by 5916.67% to -$722000.0 in 2022, then decreased by 19.67% to -$864000.0 in 2023, then surged by 326.04% to $2.0 million in 2024, then tumbled by 208.91% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Non Operating Income are -$2.1 million (Q4 2025), -$449000.0 (Q3 2025), and -$420000.0 (Q2 2025).